Why is this draft Medicare coverage significant for Pacific Edge (ASX:PEB) investors?

The draft policy distinguishes the use of Cxbladder tests for microhaematuria patients from broader oncology genetic testing policies that previously lacked coverage.

How does the Novitas draft policy create a "competitive moat" for Pacific Edge?

The draft coding article (DA60424) specifically names Cxbladder Triage (0363U) and Triage Plus (0420U) for reimbursement while excluding other urine-based biomarkers.

What clinical problem do the Cxbladder Triage tests solve for patients and urologists?

The tests help risk-stratify intermediate-risk patients with microhaematuria who want to avoid or defer invasive cystoscopy procedures.

What role did the American Urological Association (AUA) play in this decision?

The draft coverage follows a focused reconsideration process that included testimony and evidence from the American Urological Association and other clinical stakeholders.

Is this Medicare coverage for Cxbladder finalized and guaranteed?

No; as of this announcement, the policy is still in the "draft" stage (DL40378). While a draft LCD is a very positive signal, it must go through a public comment and review period before it is finalized, meaning there is still a regulatory window where the terms could be modified before becoming an active policy.

Pacific Edge secures vital Medicare draft coverage

Q: What was the major announcement regarding Pacific Edge (ASX:PEB)?

Pacific Edge announced that the US Medicare administrative contractor, Novitas, has published a draft Local Coverage Determination (LCD) that includes positive coverage for its Cxbladder Triage and Triage Plus tests.

Written by Mahathir BayenaPublished May. 14 2026Last Updated May. 14 2026

Pacific Edge (ASX:PEB) has announced that Novitas has published a draft Local Coverage Determination and associated Local Coverage Article that includes positive coverage for its Cxbladder Triage and Triage Plus tests.

The draft LCD, titled ‘Urine-based Biomarkers in Patients with Microhaematuria' (DL40378), marks the first time haematuria evaluation has been established as a covered Medicare benefit, distinguishing this patient population from those under existing non-coverage policies for oncology genetic testing.

The rationale provided by Novitas highlights the clinical necessity of multi-analytes in urine-based biomarkers in risk-stratifying intermediate-risk patients with microhaematuria who are considering deferring more invasive cystoscopy procedures.

By providing explicit coding guidance for Cxbladder Triage (0363U) and Triage Plus (0420U), the draft policy effectively creates a competitive "moat" around Pacific Edge’s microhaematuria business, as no other UBBs were included for reimbursement in the associated draft article.

Pacific Edge CEO Dr Peter Meintjes hailed the decision as a reflection of the substantial clinical evidence developed by the company and the urgent needs identified by expert panels.

The decision follows a focused reconsideration process involving input from the American Urological Association and other clinical stakeholders during a contractor advisory committee meeting held earlier in 2026.